A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
Gregory M. Coté(Harvard University), David M. Thomas(New South Wales Department of Health), Priscilla Merriam(Dana-Farber Cancer Institute), Lucille Sebastian(Heidelberg University), Rosemary Harrup(University of Tasmania), Peter Grimison(The University of Sydney), Mason Aberoumand(The University of Sydney), John P. Grady(Garvan Institute of Medical Research), E. Choy(Global Cancer Institute), Suzanne George(Dana-Farber Cancer Institute), Michael Millward(The University of Western Australia), Mandy L. Ballinger(Garvan Institute of Medical Research), David Espinoza(The University of Sydney), Subotheni Thavaneswaran(The University of Sydney), Frank Lin(Respiratory Clinical Trials), R. John. Simes(Respiratory Clinical Trials), Michael P. Brown(Royal Adelaide Hospital), Bruce A. Littlefield(Eisai (Japan)), George Demetri(Dana-Farber Cancer Institute), Emanuele Mazzola(Dana-Farber Cancer Institute)
Cited by 3
Related Papers
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|733
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2020|530
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
|Immunity|2017|489